Source:http://linkedlifedata.com/resource/pubmed/id/11119432
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2001-1-22
|
| pubmed:abstractText |
This seroprevalence report examines serologic evidence of hepatitis B immunization or infection and associated demographic/behavioral factors in adolescent (aged 12-20) subjects enrolled in a nontherapeutic clinical trial at 43 Pediatric AIDS Clinical Trials Group (PACTG) clinical centers. Subjects (n = 94) infected with the human immunodeficiency virus (HIV) through sexual activity were categorized as hepatitis B virus (HBV)-immunized, HBV-infected, or nonimmune by hepatitis B serology performed on specimens collected within the subject's first 48 weeks on study (1993-1995). Sixteen percent of the 94 serologically classified subjects were immunized; 19% HBV-infected; 65% nonimmune. Of the three risk factor scores examined (sociodemographic, sexual, and substance abuse), substance use alone demonstrated a significant difference among groups (despite virtually no reported injecting drug behavior), with the sexual risk score exhibiting marginally significant differences. Logistic regression analysis (restricted to nonimmunized subjects) showed that male-male sexual activity raised the odds of HBV infection by a factor of 5.14 (95% confidence interval [CI]: 1.45-18. 23) relative to heterosexual activity; and that for every one point increase on the substance abuse risk scale the odds of infection increased 5% (95% CI: 0.99-1.10). The HBV infection rate in PACTG 220 HIV-positive females is twice United States population-based rates; the rate in PACTG 220 HIV-positive males is nearly seven times higher. Past immunization efforts in this population appear to have been based on sexual activity volume without regard to injecting-drug use in sex partners.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
X
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1087-2914
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
651-7
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11119432-Adolescent,
pubmed-meshheading:11119432-Adult,
pubmed-meshheading:11119432-Child,
pubmed-meshheading:11119432-Female,
pubmed-meshheading:11119432-HIV Seropositivity,
pubmed-meshheading:11119432-Hepatitis B,
pubmed-meshheading:11119432-Hepatitis B Antibodies,
pubmed-meshheading:11119432-Hepatitis B Vaccines,
pubmed-meshheading:11119432-Humans,
pubmed-meshheading:11119432-Logistic Models,
pubmed-meshheading:11119432-Male,
pubmed-meshheading:11119432-Population Surveillance,
pubmed-meshheading:11119432-Predictive Value of Tests,
pubmed-meshheading:11119432-Risk Factors,
pubmed-meshheading:11119432-Seroepidemiologic Studies,
pubmed-meshheading:11119432-Sexual Behavior,
pubmed-meshheading:11119432-Socioeconomic Factors,
pubmed-meshheading:11119432-Substance Abuse, Intravenous,
pubmed-meshheading:11119432-United States,
pubmed-meshheading:11119432-Vaccination
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Serologic examination of hepatitis B infection and immunization in HIV-positive youth and associated risks. The Pediatric AIDS Clinical Trials Group Protocol 220 Team.
|
| pubmed:affiliation |
Pediatric, Adolescent, and Maternal AIDS Branch, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland 20892-7510, USA. ar44n@nih.gov
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|